menu
    • menu

    Company profile for ProLynx

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ProLynx is a biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company improves properties of off-patent therapeutics for its own portfolio, and applies its technology to extend half-lives of drug candidates of pharmaceutical companies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ProLynxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    455 Mission Bay Blvd South San Francisco, CA 94158
    Telephone
    Telephone
    (415) 552-5306​
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.prolynxllc.com/index.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ProLynx Publishes Once Monthly Semaglutide in PNAS
    ProLynx Publishes Once Monthly Semaglutide in PNAS

    02 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/prolynx-announces-publication-of-its-once-monthly-semaglutide-in-the-proceedings-of-the-national-academy-of-sciences-302318520.html

    PR NEWSWIRE
    02 Dec 2024
    Share Share
    ProLynx Reports Preclinical Results Of Monthly Semaglutide
    ProLynx Reports Preclinical Results Of Monthly Semaglutide

    21 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/21/2933785/30541/en/ProLynx-announces-preclinical-results-of-long-acting-semaglutide-requiring-once-monthly-dosing.html

    GLOBENEWSWIRE
    21 Aug 2024
    Share Share
    ProLynx announces of the Ph II Topology trial of its DNA-damaging agent PLX03
    ProLynx announces of the Ph II Topology trial of its DNA-damaging agent PLX03

    25 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/25/2851654/30541/en/ProLynx-announces-initiation-of-the-Phase-II-Topology-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-triple-negative-breast-cancer-at-the-Institut-Curie.html

    GLOBENEWSWIRE
    25 Mar 2024
    Share Share
    ProLynx announces initiation of Phase I/II trial of DNA-damaging agent PLX038
    ProLynx announces initiation of Phase I/II trial of DNA-damaging agent PLX038

    05 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/05/2823569/30541/en/ProLynx-announces-initiation-of-Phase-I-II-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-patients-with-rare-CNS-tumors-at-the-National-Cancer-Institute-NCI.html

    GLOBENEWSWIRE
    05 Feb 2024
    Share Share
    ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors
    ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors

    24 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/24/2815405/30541/en/ProLynx-announces-a-publication-proposing-that-a-long-acting-prodrug-of-SN-38-could-be-effective-in-treating-Sacituzumab-Govitecan-Resistant-Tumors.html

    GLOBENEWSWIRE
    24 Jan 2024
    Share Share
    ProLynx announces initiation of Ph II trial of its DNA-damaging agent PLX038
    ProLynx announces initiation of Ph II trial of its DNA-damaging agent PLX038

    07 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/07/2530299/30541/en/ProLynx-announces-initiation-of-Phase-II-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-patients-with-platinum-resistant-Ovarian-Cancer-at-the-Mayo-Clinic.html

    GLOBENEWSWIRE
    07 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search